EGFR and non-small cell lung carcinoma: Interestingly, treatment with EGFR tyrosine kinase inhibitor (EGFR-TKI) reduced the EREG expression level in EGFR-mutant NSCLC cells, and EREG knockdown resulted in the inhibition of cell proliferation and invasion, suggesting that EREG plays an important oncogenic role in NSCLC progression [60].